Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Neuland Laboratories
Mid Cap•1,643 Employees•IPO 1994
Current Price
₹12152.00
-422 (-3.36%)Updated
Today's Range
12013
₹12152.00
12637
52 Week Range
52W Low₹10400.15
52W High₹19747.00
₹12152.00
Downside16.84%
Upside62.50%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹17,552.57 Cr
Market Cap
Total market value of companyP/E Ratio
94.84
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
11.57
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹139.62
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
7.93%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
18.70%
ROCE
Return on Capital Employed. >15% is goodNet Margin
11.37%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
74.13%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
14.13%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
-33.40%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
-83.10%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.10
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹1188.48
Book Value
Net asset value per shareDividend Yield
0.09%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
32.60%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
5 points- •Strong Returns: ROE of 14.8% and ROCE of 18.7% indicate efficient capital utilization and strong operational efficiency, reflecting the company's ability to generate profits from shareholder funds and overall capital.
- •Healthy Operating Margin: An Operating Profit Margin (OPM) of 17.6% suggests robust core business profitability and effective cost management, which is crucial for sustained financial health and competitive advantage.
Weaknesses
7 points- •High P/E Ratio: The company's high P/E ratio of 150.00 suggests a premium valuation compared to its earnings, potentially indicating overvaluation and increasing the risk of future price corrections for investors.
- •Sharp Quarterly Profit Decline: A significant 83.1% decline in recent quarterly profit raises serious concerns about earnings stability and sustainability, requiring close monitoring of underlying operational challenges.
Opportunities
2 points- •Operating in the Pharmaceuticals industry, the company can capitalize on global healthcare spending trends, increasing demand for specialized drugs, and advancements in API manufacturing, driving future revenue growth.
- •The company's strong financial structure with low debt-to-equity (0.10) provides significant flexibility to pursue strategic acquisitions or expand R&D initiatives, fostering long-term growth and market leadership.
Threats
3 points- •The highly competitive Pharmaceuticals sector, with peers showing robust sales and profit growth, poses a significant threat, potentially leading to market share erosion and pricing pressures for the company.
- •The company's recent sharp decline in quarterly sales by 33.4% and profit by 83.1% indicates a risk of losing competitive edge and market relevance if these negative trends persist against industry peers.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
Recent Insider Transactions
| Insider Name | Transaction Date | Filing Date | Total Shares | Change | Price | Action |
|---|---|---|---|---|---|---|
Sucheth Rao Davuluri | 25 Feb 2025 | 25 Feb 2025 | 2.58 L | 79,573 | - | SELL |
Davuluri Ownership Trust | 25 Feb 2025 | 25 Feb 2025 | 32.54 L | 32.54 L | - | BUY |
Davuluri Vijaya Rao | 24 Feb 2025 | 25 Feb 2025 | 5,000 | 6.08 L | - | SELL |
Davuluri Ramamohan Rao | 24 Feb 2025 | 25 Feb 2025 | 2.09 L | 25.66 L | - | SELL |
Davuluri Ownership Trust | 28 Feb 2025 | 01 Mar 2025 | 33.33 L | 79,462 | - | BUY |
Saharsh Rao Davuluri | 28 Feb 2025 | 01 Mar 2025 | 2.08 L | 79,462 | - | SELL |
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹13769.67 | +₹1617.67 | +13.31% |
| R3 | ₹13145.67 | +₹993.67 | +8.18% |
| R2 | ₹12891.33 | +₹739.33 | +6.08% |
| R1 | ₹12521.67 | +₹369.67 | +3.04% |
| PIVOT | ₹12267.33 | 115.33 | 0.95% |
| CURRENT | ₹12152.00 | - | - |
| S1 | ₹10649.67 | -₹1502.33 | -12.36% |
| S2 | ₹11273.67 | -₹878.33 | -7.23% |
| S3 | ₹11643.33 | -₹508.67 | -4.19% |
| S4 | ₹11897.67 | -₹254.33 | -2.09% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+5.4% vs avg
0.50L
(13 Mar 2026)Delivery %+11.6% vs avg
41.2%
(13 Mar 2026)Avg Volume (20D)20-day average
0.47L
(13 Feb - 13 Mar)Avg Delivery %Trend ↑
29.6%
(13 Feb - 13 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Acutaas Chemicals Ltd
93.50 %
Highest Dividend Yield
Pfizer Ltd
3.28 %
Peer Comparison
| Company Name |
|---|
 Acutaas Chemicals Ltd |
 Alembic Pharmaceuticals Ltd |
 Astrazeneca Pharma India Ltd |
 Caplin Point Laboratories Ltd |
 Cohance Lifesciences Ltd |
 Concord Biotech Ltd |
 Emcure Pharmaceuticals Ltd |
 ERIS Lifesciences Ltd |
 Granules India Ltd |
 J B Chemicals & Pharmaceuticals Ltd |
 Jubilant Pharmova Ltd |
 Natco Pharma Ltd |
 Pfizer Ltd |
 Piramal Pharma Ltd |
 |
 Sun Pharmaceutical Industries Ltd |
 Wockhardt Ltd |
About
Neuland Laboratories Ltd
Neuland Laboratories Limited is a global manufacturer and supplier of active pharmaceutical ingredients (APIs). Its primary business centers around the production and distribution of these essential components used in the creation of pharmaceutical drugs. The company serves a broad international market, with operations spanning India, Europe, the United States, and other countries around the world, signifying a significant global reach and established distribution network.
A key aspect of Neuland Laboratories' business model is its provision of custom manufacturing solutions. This service allows pharmaceutical companies to outsource the production of specific APIs tailored to their unique needs and formulations. This approach offers flexibility and scalability to clients, enabling them to focus on research, development, and marketing while leveraging Neuland's manufacturing expertise and infrastructure.
Further enhancing its service portfolio, Neuland Laboratories offers specialized peptide synthesis services. Peptides are short chains of amino acids that play crucial roles in various biological processes, making them important components in a range of therapeutic applications. The company's proficiency in this area demonstrates a commitment to advanced pharmaceutical technologies and a capability to cater to the increasing demand for complex pharmaceutical molecules.
Established in 1984 and headquartered in Hyderabad, India, Neuland Laboratories has a long history in the pharmaceutical industry. This long-standing presence suggests experience in navigating regulatory landscapes, managing complex production processes, and building strong relationships with clients and regulatory bodies across different global markets. The company’s sustained operation and global footprint highlight its ability to adapt and thrive in a dynamic and competitive industry.
COMPANY FACTS - NEULANDLAB
Registered Address
11th Floor (5th Level), Phoenix IVY Building, Plot No. 573A-, III, Road No. 82, Jubilee Hills
Hyderabad
TELANGANA
IN
Tel: 914067611600
Website:https://www.neulandlabs.com/
Investor Relations:http://www.neulandlabs.com/investors/financial-reports/annual-reports/
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 1,643
IPO Date: 18/04/1994
MANAGEMENT - NEULANDLAB
Dr. Davuluri Rao
Executive Chairman of the Board
Mr. Davuluri Rao
Chief Executive Officer, Whole Time Vice Chairman of the Board
Mr. Davuluri Rao
Whole Time Vice Chairman of the Board, Joint Managing Director
Mr. Abhijit Majumdar
Chief Financial Officer
Dr. Sharadsrikar Kotturi
Chief Scientific Officer
Ms. Sarada Bhamidipati
Compliance Officer, Company Secretary
Mr. Ashutosh Sinha
Chief Quality Officer
Dr. Christopher Cimarusti
Non-Executive Non-Independent Director
Ms. Pallavi Bhakru
Additional Independent Director
Mr. Prasad Menon
Additional Independent Director
Mr. Sugata Sircar
Additional Independent Director
Mr. Homi Khusrokhan
Non-Executive Independent Director
Investor Questions Answered
Neuland Laboratories Ltd (NEULANDLAB) Stock FAQs
Get answers to the most common questions about Neuland Laboratories Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Neuland Laboratories Ltd (NEULANDLAB) is ₹12,152. Today, the stock has declined by ₹422.00 (3.36%), trading in a range of ₹12,013 to ₹12,637. The stock opened at ₹12,637 with a trading volume of 50,055 shares.
Neuland Laboratories Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹17,552.57 crores, P/E ratio of 94.84, ROE of 7.93%, and ROCE of 18.70%. The dividend yield stands at 0.09%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Neuland Laboratories Ltd (NEULANDLAB) is ₹19,747, while the 52-week low is ₹10,400.15. Currently trading at ₹12,152, the stock is 18.7% away from its 52-week low and 38.5% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Neuland Laboratories Ltd stock at ₹12,152 depends on multiple factors. The stock is currently trading with a P/E ratio of 94.84 and P/B ratio of N/A. Today's performance shows a loss of 3.36%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Neuland Laboratories Ltd offers a dividend yield of 0.09%, which means for every ₹100 invested at the current price of ₹12,152, you can expect to receive approximately ₹0.09 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Neuland Laboratories Ltd's key financial metrics include: P/E Ratio: 94.84, P/B Ratio: N/A, ROE: 7.93%, ROCE: 18.70%, Dividend Yield: 0.09%, EPS: ₹139.62, Book Value: ₹1,188.48, Debt-to-Equity: 0.10, and Current Ratio: N/A. The company's market cap stands at ₹17,552.57 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Neuland Laboratories Ltd stock opened at ₹12,637 and is currently trading at ₹12,152, showing a decline of ₹422.00 (3.36%). The intraday high is ₹12,637 and low is ₹12,013. The trading volume stands at 50,055 shares, indicating moderate market participation today.
Neuland Laboratories Ltd has a Price-to-Earnings (P/E) ratio of 94.84, which means investors are willing to pay ₹94.84 for every ₹1 of earnings. With an EPS of ₹139.62, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Neuland Laboratories Ltd has a market capitalization of ₹17,552.57 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹12,152) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Neuland Laboratories Ltd has a book value of ₹1,188.48 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹12,152, which is 922.5% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Neuland Laboratories Ltd has a Return on Equity (ROE) of 7.93% and Return on Capital Employed (ROCE) of 18.70%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Neuland Laboratories Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Neuland Laboratories Ltd has a debt-to-equity ratio of 0.10, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Neuland Laboratories Ltd has an Earnings Per Share (EPS) of ₹139.62, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹12,152 and P/E ratio of 94.84, investors are paying 94.84 times the annual earnings per share. This strong EPS indicates robust profitability. Track EPS growth over quarters to assess earnings momentum.
Neuland Laboratories Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Neuland Laboratories Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Neuland Laboratories Ltd stock, consider: 1) Fundamental Analysis - Review P/E (94.84), ROE (7.93%), debt-to-equity (0.10), and growth rates. 2) Technical Analysis - Check 52-week range (₹10400.15 - ₹19747.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹12152.00) with book value (₹1188.48) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Neuland Laboratories Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹12,152 is 121420x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Neuland Laboratories Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹10400.15 - ₹19747.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.10 indicates leverage. 4) Liquidity Risk - Based on trading volume of 50,055 shares. 5) Valuation Risk - P/E of 94.84 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Neuland Laboratories Ltd operates in the industry with key metrics: P/E ratio of 94.84, ROE of 7.93%, market cap of ₹17,552.57 crores, and dividend yield of 0.09%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.10), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Neuland Laboratories Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹12,152, with a 52-week range of ₹10400.15 to ₹19747.00. Based on fundamentals like P/E (94.84), ROE (7.93%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Neuland Laboratories Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹12152.00. 2) Fundamental Deterioration - Declining ROE (currently 7.93%), increasing debt (D/E: 0.10), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Neuland Laboratories Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.09%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu